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Background: Stromal-derived-factor-1 (SDF-1) and the G-protein-coupled-receptor CXCR4 are involved in 
several physiological and pathological processes including breast cancer spread and progression. Several 
CXCR4 antagonists have currently reached advanced development stages as potential therapeutic agents for 
different diseases. Results: A small series of novel CXCR4 ligands, based on a 2-(1H-indol-1-yl)-
benzohydrazide scaffold, have been designed and synthesized. Their orientation into CXCR4 active site was 
predicted by molecular docking and confirmed by whole cell-based [125I]-SDF-1 ligand competition binding 
assays. One of the synthesized compounds was particularly active in blocking SDF-1-induced breast cancer 
cell motility, proliferation and downstream signaling activation in different breast cancer cell models and co-
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culture systems. Conclusion: The newly synthesized compounds represent suitable leads for the 
development of innovative therapeutic agents targeting CXCR4. 
 
 
CXCR4 (C-X-C chemokine receptor type 4), also known as CD184 (cluster of differentiation 184) or fusin, 
is a seven transmembrane G-protein coupled receptor (GPCR) belonging to rhodopsin-like GPCR family 
[1,2]. CXCR4, first identified as one of the two co-receptors required for the fusion of HIV envelope with the 
membrane of the targeted cell, was found to be widely expressed in the hematopoietic and immune systems, 
where it is likely involved in several physiological and pathological processes [3,4]. 
 
The natural CXCR4 ligand was recognized to be the Stromal Derived Factor-1 (SDF-1), an eight-kDa 
homeostatic chemokine peptide also known as CXCL12, which promotes chemotaxis after binding the 
receptor [5]. The SDF-1/CXCR4 interaction plays a key role in pathological processes, such as HIV 
infection, inflammation and cancer onset and progression, thus representing an appealing target for the 
development of innovative broad-spectrum therapeutics [6,7].  
 
The mounting evidence of the crucial role played by CXCR4 in several diseases has encouraged the 
development of compounds that are able to modulate its biological activity. In the past few years, numerous 
compounds belonging to different chemical classes, have demonstrated capacity to block SDF-1/CXCR4 
interaction (Figure 1). Some of these compounds are currently under clinical trials for the treatment of 
various diseases including cancers, hematologic and vascular diseases, HIV infection, and other immune 
system disorders involving the modulation of the SDF-1/CXCR4 axis, such as rheumatoid arthritis and lupus 
[8].  
The first identified CXCR4 antagonists were peptide derivatives that, despite the unfavorable 
pharmacokinetics and metabolic instability, have been the starting point for building up a pharmacophore 
model subsequently adopted for the design of simpler non-peptide antagonists [8,9] 
 
3 
 
Among the non-peptide ligands, a macrocyclic “bicyclam” derivative, called AMD3100, also known as 
Plerixafor (1), has been the first CXCR4 antagonist approved by the FDA for diseases involving the 
mobilization of hematopoietic stem cells [10] and presently it is in advanced clinical trials for other 
pathological conditions [11-15]. Despite the noteworthy potency, the clinical applicability of this compound 
is yet limited by a poor bioavailability due to its high overall positive charge at physiologic pH. 
Furthermore, the small molecule AMD070 (2), the lead of a series of compounds containing at the same time 
a benzimidazole and a tetrahydroquinoline moiety in their structure,  demonstrated a remarkable antagonistic 
activity after oral administration and it is currently under advanced clinical investigation for the prophylaxis 
of HIV infection [16-18].  
 
 
 
Figure 1. Chemical structures of known antagonists of CXCR4. 
 
The evolution in the search of alternative structure for CXCR4 antagonists brought to the identification of 
poly-substituted indoles, among them compound 3 represents the most promising prototype active in human 
CXCR4 transfected Chinese hamster ovary (CHO) cells in  a [125I]-SDF-1 radio-ligand assay [19].  
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These compounds were abandoned due to their high protonation degree ‘in vivo’, which precludes an 
adequate tissues distribution. However, various groups functionalizing the indole nucleus could yet 
guarantee spatial requirements for key interactions in the previously reported pharmacophore model, as 
shown by molecular modeling [20]. A further improvement in the definition of CXCR4 receptor was the 
discovery of the orally active isothiourea ligand IT1t (4), which was co-crystallized with the receptor 
[21,22]. 
Herein, we report the identification of a small series of CXCR4 antagonists based on a 2-(1H-indol-1-yl)-N’-
arylbenzohydrazide moiety (FIL1-3, Figure 2) with typical small molecule drug characteristics reflecting 
potential favorable pharmacokinetics and many possibilities to be optimized.  
 
Figure 2. Structures of studied compounds. 
 
Since the chemokine SDF-1α and its cognate receptor CXCR4 play a crucial role in breast cancer spread and 
progression [23,24], the effects of synthesized compounds have been tested in different breast cancer cell 
models and in co-culture systems by using specific biological assays, such as cell proliferation and wound-
healing assays, where they revealed interesting anticancer properties. 
 
In particular, one of the tested compounds, FIL2, was particularly active in blocking SDF-1α-dependent cell 
motility, proliferation and downstream signaling activation in estrogen-receptor negative and positive breast 
cancer cells as well as in experimental cell models for acquired endocrine resistance. A specific [125I]-SDF-
1α binding assay has confirmed that the above properties were unambiguously due to CXCR4 inhibition. 
This compound was also able to inhibit the effects of cancer-associated fibroblasts (CAFs), key players in the 
breast tumor microenvironment, on cancer progression.    
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Based on all the promising results we obtained, the newly synthesized compounds could be considered leads 
for the development of new selective CXCR4 antagonists as novel tools for the treatment of breast cancer 
and other CXCR4-related diseases. 
 
MATERIALS AND METHODS 
Molecular modelling and docking simulations  
The molecular modelling simulations were performed on an Apple Mac pro 2.66 GHz Quad‐Core Intel 
Xeon, Running Ubuntu 12.04. The CXCR4 protein was downloaded from the Protein Data Bank, accession 
code: 3ODU [20] and prepared using the Protein Preparation Wizard tool of Maestro [25]. Putative inhibitors 
were built and prepared in Maestro and docked with GLIDE, using the SP mode. Images were created using 
MOE [26]. 
 
Chemical synthesis 
General experimental information is reported in ref. 27. The purity of FIL1-3 was > 96 %, as determined by 
HPLC.  
 
2-(5-Bromo-1H-indol-1-yl)-N'-phenylbenzohydrazide (FIL1) 
To a stirred solution of 2-(5-bromo-1H-indol-1-yl)benzoic acid 1 [27] (0.060 g; 0.190 mmol) in DMF (1 mL) 
CDI (0.031;  0.190 mmol) was added in 10 min. A solution of phenylhydrazine (0.020 g; 0.190 mmol) in 
DMF (1 mL) was slowly added in 15 min. The reaction mixture was heated to 60°C for 8 hours. The solvent 
was then evaporated and the solid residue obtained was taken up into ethyl acetate. The resulting solution 
was sequentially debated with 5% HCl solution and brine. After evaporation of the solvent, the crude product 
was purified by column chromatography (toluene/ethyl acetate/methanol/ammonium hydroxide, 10/1/1/0.25, 
as eluent). The title compound was separated as an orange amorphous solid in 22% yield. 1H NMR (300 
MHz, MeOD) δ 7.82 (s, 1H), 7.69-7.60 (m, 3H), 7.44-7.37 (m, 3H), 7.24-7.06 (m, 5H), 7.01-6.81 (m, 2H). 
13C NMR (75 MHz, MeOD) δ 164.0, 148.8, 144.7, 143.9, 142.8, 136.6, 135.9, 130.6, 130.2, 129.4, 129.0, 
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129.9, 128.8, 128.5, 128.2, 128.0, 127.9, 125.9, 120.4, 118.9, 112.6. HRMS calcd for C21H16BrN3O 
405.0477, found 405.0420. IR (KBr) max:  1676 cm-1. 
 
2-(5-Bromo-1H-indol-1-yl)-N'-(pyrazin-2-yl)benzohydrazide (FIL2)  
This compound was prepared following the procedure applied for FIL1 starting from pyrazin-2-yl-hydrazine 
(0.021 g; 0.190 mmol). The pure compound was obtained as a brown amorphous solid in 50% yield. 1H 
NMR (300 MHz, MeOD) δ  8.11 (s, 1H), 7.99-7.88 (m, 2H), 7.73-7.62 (m, 3H), 7.67 (t, 1H, J = 7.6 Hz), 
7.44 (d, 1H, J = 7.9 Hz), 7.29 (d, 1H,  J = 3.2 Hz), 7.20-7.09 (m, 1H), 6.97 (d, 1H,  J = 4.7 Hz), 6.58 (d, 1H, 
J = 3.2 Hz). 13C NMR (75 MHz, MeOD) δ 167.0, 140.8, 137.8, 135.9, 133.0, 131.3, 130.5, 130.2, 129.9, 
128.7, 128.2, 128.0, 127.8, 127.7, 124.5, 124.2, 122.9, 110.9, 102.3. HRMS calcd for C19H14BrN5O 407.0382 
found 407.0407. IR (KBr) max: 1656 cm-1. 
 
2-(5-Bromo-1H-indol-1-yl)-N'-(quinoxalin-2-yl)benzohydrazide (FIL3) 
This compound was prepared following the procedure applied for FIL1 starting from quinoxalin-2-yl-
hydrazide (0.030 g; 0.190 mmol). The pure compound was obtained as a purple solid in 37% yield. 1H NMR 
(300 MHz, MeOD) δ 8.32 (d, 1H, J = 7.5 Hz), 8.10 (d, 1H, J = 9.1 Hz), 7.82 (d, 1H, J = 9.1 Hz), 7.79-7.69 
(m, 2H), 7.55 (t, 2H, J = 7.7 Hz), 7.42-7.35 (m, 3H), 7.20-7.05 (m, 3H), 6.59 (d, 1H, J = 3.2 Hz). 13C NMR 
(75 MHz, MeOD) δ 159.5, 158.0, 137.3, 134.0, 133.3, 132.5, 129.0, 128.8, 128.0, 127.6, 127.0, 126.2, 125.4, 
124.2, 123.0, 122.2, 121.5, 120.0, 118.8, 117.6, 111.3, 108.5, 102.1. HRMS calcd for C23H16BrN5O 457.0538 
found 457.0525. IR (KBr) max:  1693 cm-1. 
 
 
Biological materials and methods 
Reagents and antibodies 
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SDF-1α and [125I]-SDF-1α were obtained from Sichim and Perkin-Elmer, respectively. Antibodies used for 
immunoblotting were: total Akt, phosphoAktSer437 and GAPDH (Santa Cruz Biotechnology), MAPK and 
phosphoMAPKThr202/Tyr204 (Cell Signaling Technology). Peroxidase-coupled secondary antibodies goat anti-
mouse or anti-rabbit were obtained from Santa Cruz Biotechnology and the enhanced chemiluminescence 
system was from Amersham Pharmacia. Collagenase, 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide reagent/MTT and Coomassie Brilliant Blue were obtained from Sigma. TRIZOL reagent was from 
Invitrogen. RETROscript kit was purchased from Promega. 
 
Cell culture  
MCF-10A normal breast epithelial cells were grown in Dulbecco’s modified Eagle’s medium-F12 plus 
glutamax containing 5% Horse Serum, 1 mg/ml penicillin–streptomycin, 0.5 mg/ml hydrocortisone, and 
10mg/ml insulin. Human estrogen receptor (ER)-negative MDA-MB-231 breast cancer cells were cultured in 
DMEM medium supplemented with 10% Fetal Bovine Serum, 0.1 nmol/L nonessential amino acid, 2 
mmol/L L-glutamine, and 50 units/ml penicillin/streptomycin. Human ER-positive MCF-7 breast cancer 
cells were cultured in DMEM/F-12 medium supplemented with 5% Newborn Calf Serum, 0.1 nmol/L 
nonessential amino acid, 2 mmol/L L-glutamine, and 50 units/ml penicillin/streptomycin. Tamoxifen-
resistant (TR) cells derived from MCF-7 cultured with 4-OH-tamoxifen over a period of 12 months and 
long-term estrogen-deprived cells (LTED) were derived from MCF-7 after six-month estrogen deprivation 
were obtained as previously described [28]. Subconfluent cell cultures, synchronized for 48 hours in medium 
without phenol red and serum, were used for all experiments. 
 
CAF isolation and conditioned medium systems  
Human cancer-associated fibroblasts (CAFs) were obtained from three specimen of human primary breast 
cancers as described [29]. Briefly, following digestion of small tumor pieces (collagenase 500 U/mL in 
Hank’s balanced salt solution, at 37°C for 2 hours) and differential centrifugation (90 g for 2 minutes), the 
supernatant containing CAFs was centrifuged (500 g for 8 minutes), resuspended, and cultured in RPMI-
1640 medium supplemented with 15% Fetal Bovine Serum, and antibiotics. CAFs between 4-10 passages 
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were used, tested by mycoplasma-presence, authenticated by morphology and FAP and α-SMA expression. 
For generation of conditioned media, CAFs were incubated with medium without phenol red and serum for 
48-72 hours. Conditioned media were collected, centrifuged to remove cellular debris and utilized in 
respective experiments.  
 
RT-PCR assays 
Total cellular RNA was extracted using TRIZOL reagent as suggested by the manufacturer. The purity and 
integrity were checked spectroscopically and by gel electrophoresis before carrying out the analytical 
procedures. Two microgram of total RNA were reverse transcribed in a final volume of 20 µL using a 
RETROscript kit as suggested by the manufacturer. The cDNAs obtained were amplified by PCR using the 
following primers: 5’-TTACCCGCAAAAGACAAGT-3’ (SDF1-α forward) and 5’-
AGGCAATCACAAAACCCAGT-3’ (SDF1-α reverse), 5’-AATCTTCCTGCCCACCATCT-3’ (CXCR4 
forward) and 5’-GACGCCAACATAGACCACCT-3’ (CXCR4 reverse), 5’-
CTCAACATCTCCCCCTTCTC-3’ (36B4 forward) and 5’-CAAATCCCATATCCTCGTCC-3’ (36B4 
reverse). Negative controls containing water instead of first strand cDNA were utilized. 
 
Wound-healing assays 
For the measurement of cell migration during wound healing, confluent cell cultures were incubated in 
phenol-red and serum-free medium for 24 hours before the beginning of the experiment. Cell monolayers 
were then scraped, washed to remove debris and treated as indicated in the respective experiments. Wound 
closure was monitored over 24 hours. Cells were then fixed, stained with Comassie Brillant Blue and 
photographed after wounding under phase contrast microscopy at 10X magnification. Pictures represent one 
of three-independent experiments. 
 
Cell proliferation assays  
MTT assays. Cells (2 x 104 cells/well) were plated in 24-well plates and treated as indicated for 3 days. The 
MTT assay was performed as the following: 100 µL MTT solution in PBS (2 mg/mL) was added into each 
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well and allowed to incubate at 37°C for 2 hours followed by media removal and solubilization in 500 µL 
dimethyl sulfoxide (DMSO). After shaking the plates for 15 minutes, the absorbance at 570 nm was 
measured in each well, including the blanks. Cell proliferation was expressed as fold change relative to 
vehicle-treated cells. A minimum of three experiments, containing eight different doses of FIL2 in triplicate, 
was combined for IC50 calculations. The absorbance readings were used to determine the IC50 using 
GraphPad Prism 4 (GraphPad Software). Briefly, values were log-transformed, normalized, and nonlinear 
regression analysis was used to generate a sigmoidal dose– response curve to calculate IC50 values. 
Soft agar growth assays. Cells (104/well) were plated in 0.35% agarose with 5% charcoal stripped-FBS in 
phenol red-free media (4 mL), with 0.7% agarose base in six-well plates. After two days, media containing 
vehicle or indicated treatments were added to the top layer, and replaced every 2 days. After 14 days, 300 µL 
of MTT reagent was added to each well and incubated at 37°C for 4 hours. Plates were then placed at 4°C 
overnight and colonies > 50µm diameter from triplicate assays were counted. The data are representative of 
three independent experiments, each performed in triplicates. 
 
Immunoblot analysis  
Total protein lysates were subjected to SDS–PAGE as described [30]. Briefly, cells were harvested in cold 
PBS and resuspended in lysis buffer containing HEPES (20 mmol/L, pH 8), EGTA (0.1 mmol/L), MgCl2 (5 
mmol/L), NaCl (0.5M), glycerol (20%), Triton (1%), and protease inhibitors (0.1 mmol/L sodium 
orthovanadate, 1% phenylmethylsulfonylfluoride, and 20 mg/mL aprotinin). Equal amounts of total protein 
lysates were resolved on a 11% SDS–polyacrylamide gel, transferred to a nitrocellulose membrane, and 
probed with appropriate antibodies as indicated in the respective experiments. Band intensities representing 
relevant proteins were measured by Scion Image laser densitometry scanning program (Scion Corporation) 
and standard deviations along with associated P values for the biological replicates were determined by using 
GraphPad-Prism4 software (GraphPad Inc., San Diego, CA). Immunoblots show one representative image of 
three separate experiments.  
 
[125I]-SDF-1α competition binding assays 
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MDA-MB-231 cells were harvested with versene reagent and washed twice in PBS. Ligand binding 
experiments were performed using 1 nM of [125I]-SDF-1α (specific activity, 2.200 Ci/mmol) in a final 
volume of 100 µL binding buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 150 mM NaCl, 5 mM MgCl2, 5% 
bovine serum albumin) containing 5 x 105 cells/well in the presence of serially diluited concentrations of 
unlabeled SDF-1α or FIL2 compound. Nonspecific binding was determined by adding 150 nM of unlabeled 
SDF-1α. Samples were incubated for 60 minutes at 4°C. After incubation, cells were washed twice with 300 
µL wash buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 500 mM NaCl, 5 mM MgCl2). Bound ligands were 
determined by standard gamma counting techniques. At least three independent experiments were 
performed. The binding data were analyzed by nonlinear regression using the GraphPad PRISM program. 
 
Statistical analysis  
Data were analyzed for statistical significance using two-tailed student’s Test, GraphPad-Prism4 software. 
Standard deviations (S.D.) were shown.  
 
RESULTS AND DISCUSSION 
Design and synthesis 
The isothiourea ligand IT1t (4), [(E)-(6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-yl)methyl N,N'-
dicyclohexylcarbamimidothioate dihydrochloride], showing an IC50 = 48 nM in CXCR4 radioligand binding 
assay, was fruitfully used during the mapping of the active binding site of the protein, as already mentioned 
[20]. 
The rationale behind the design of the hereby-reported inhibitors was guided by two considerations: in silico 
analysis of the interactions between IT1t and CXCR4 in the crystal complex and the synthetic feasibility of 
the newly designed compounds using established procedures. In particular, we were interested in a chemical 
scaffold we could easily prepare using our recently reported method [27]. All the compounds designed using 
these criteria were docked and their binding mode analyzed to verify how well the new structures would 
mimic the IT1t binding mode (Figure 3). The first designed modification for the backbone of the new 
compounds was the replacement of the dihydroimidazo[2,1-b]thiazole system of IT1t with a flatter N-
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substituted indole that could still result in favorable interactions with Trp94. The 6,6-dimethyl motif is 
replaced by a bromine atom directed towards the Tyr116 and filling the small hydrophobic cavity present in 
that position. The benzo group linked at position 1 of indole could at the same time establish additional 
hydrophobic interactions with Val112 and support the polar carbohydrazide moiety. This latter group is also 
establishing a hydrogen bond with Asp97, a residue that is involved in a strong interaction with the 
carbamimidic group of IT1t. The final modification was the removal of bulky cyclohexyl substituents of IT1t 
with the concomitant introduction of a cyclic system linked to the N’-atom of the benzohydrazide moiety. 
Among the attempted aryl substituents, the pyrazine gave best results probably due to the possibility to 
interact further with Arg183 (Figure 3B).  
 
 
Figure 3. Docking simulation. Putative binding mode of (A) FIL1, (B) FIL2 and (C) FIL3 (represented in cyan) in the 
CXCR4 binding pocket. Co-crystallized ligand (IT1t) is represented in green. 
   
 
The three studied compounds (FIL 1-3) were obtained in moderate yields starting from a common 
intermediate, the 2-(5-bromo-1H-indol-1-yl)benzoic acid 1, whose preparation was recently described [27].  
The acid 1 was coupled with a proper hydrazine derivative by action of 1,1’-carbonyldiimidazole (CDI) in 
DMF to give compounds FIL1, FIL2 and FIL3 in 22, 50 and 37% yield, respectively (Figure 4).  
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Figure 4. Synthesis of FIL 1-3. Reagents and Conditions: (A) CDI, DMF, phenylhydrazine, 60°C (22%); (B) CDI, 
DMF, 2-hydrazinylpyrazine, 60°C (50%); (C) CDI, DMF, 2-hydrazinylquinoxaline, 60°C (37%). 
 
 
FIL2 compound blocks SDF-1α-dependent cell motility, proliferation and downstream signalling 
activation in MDA-MB-231 breast cancer cells 
It has been reported that the chemokine SDF-1α and its cognate receptor CXCR4 are expressed in breast 
carcinoma tissues and in breast cancer cell lines, and that cell clones isolated from metastatic sites (e.g., bone 
or lungs) exhibit higher levels of CXCR4 than the parental cells [31-33]. Prior to evaluating the biological 
activity of the CXCR4 antagonists, we analyzed SDF-1α and CXCR4 expression in estrogen receptor (ER)-
negative MDA-MB-231 breast cancer cells, which are well characterized in terms of their metastatic 
potential and properties. RT-PCR analysis revealed SDF-1α and CXCR4 expression in MDA-MB-231 breast 
cancer cells (Figure 5A). Given the crucial role of SDF-1α/CXCR4 signaling axis in modulating cancer cell 
migration [34], we first explored the ability of the CXCR4 antagonists that we synthesized to inhibit cell 
motility in wound-healing assays. MDA-MB-231 breast cancer cells were treated with three different 
CXCR4 antagonists (FIL1, FIL2, FIL3) at increasing concentrations (0.01, 0.1, 1, 10µM) for 24 hours. 
Figure 5B showed that FIL1 and FIL3 did non affect cell motility at all the doses tested, while FIL2 was 
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able to inhibit migration at concentrations as low as 10nM. Therefore, in agreement with the docking 
simulation, the in vitro evaluations of the CXCR4 inhibitory efficacy on cell motility also resulted in the 
selection of the antagonist FIL2 for the subsequent studies. Next, we assessed the effects of increasing 
concentrations of FIL2 compound on breast cancer cell proliferation (Figure 5C). We observed that FIL2 
treatment for 72 hours significantly reduced cell viability in MDA-MB-231 cells at all the doses tested, with 
IC50 values of 49.4 µM (95% Confidence Intervals, 30.1-81.2 µM). The activity of FIL2 compound was also 
evaluated using soft agar anchorage-independent growth. Consistently with MTT assays, FIL2 treatment 
decreased colony formation in MDA-MB-231 cells (Figure 5D). In contrast, FIL2 did not elicit any 
significant growth inhibitory effects on MCF-10A non-tumorigenic breast epithelial cells (Figure 5E). 
Taken together, these results showed that the compound FIL2 inhibits cell growth and migratory potential of 
highly invasive MDA-MB-231 breast cancer cells, interfering with the autocrine effects of SDF-1α /CXCR4 
system in these cells.  
 
Figure 5. FIL2 compound inhibits motility and growth of MDA-MB-231 breast cancer cells. (A) RT-PCR for 
SDF-1α, CXCR4 and 36B4 (internal standard). NC, negative-control. (B) Wound-healing assay in cells treated with 
vehicle (-) or increasing concentrations of FIL1, FIL2 and FIL3 compounds (0.01, 0.1, 1, 10µM). Small squares, time 0. 
(C) MTT growth assay in cells treated with vehicle (-) or FIL2 compound (0.01, 0.1, 1, 10, 50 µM). (D) Soft agar 
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anchorage-independent growth assay in cells treated with vehicle (-) or FIL2 compound (1, 10µM). Bottom panel, a 
typical well for each condition is shown. (E) MTT growth assay in MCF-10A normal epithelial breast cells treated with 
vehicle (-) or FIL2 compound (1, 10, 50, 100 µM). n.s.= non significant. *P<0.05, **P<0.005, ***P<0.0005.  
 
 
In order to verify that the CXCR4 antagonist FIL2 binds to the CXCR4 receptor, we established a whole 
cell-based [125I]-SDF-1α ligand competition binding assay. A typical result is shown in Figure 6. In a 
homologous competition binding assay, we found that MDA-MB-231 cells bind SDF-1α in a dose 
dependent-manner with IC50 value of 26.1 ± 8 nmol/L (Figure 6A). The [125I]-SDF-1α binding was replaced 
by cold SDF-1α, confirming the specificity of SDF-1 binding. FIL2 was able to inhibit [125I]-SDF-1α ligand 
binding to MDA-MB-231 cells in a heterologous competition binding assay with IC50 value of 10.9 ± 4.2 
nmol/L (Figure 6B). The binding curve was fitted to an one site binding model. These results indicate that 
FIL2 exhibits an increased affinity for the receptor compared to endogenous SDF-1α ligand and may act as a 
highly selective CXCR4 receptor antagonist. 
 
Figure 6. [125I]-SDF-1α ligand binding by MDA-MB-231 cells.  [125I]-SDF-1 competition binding assay was 
performed as described in Materials and Methods section. [125I]-SDF-1α bound to MDA-MB-231 cells was competed 
with either unlabelled SDF-1α (A) or FIL2 compound (B). The specificity of [125I]-SDF-1α binding was confirmed by a 
replacement experiment with cold SDF-1α (150-fold excess).  
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We, then, aimed to assess the ability of FIL2 compound to counteract SDF-1α-induced cell motility and 
growth. As expected, MDA-MB-231 breast cancer cells moved the farthest in either direction to close the 
‘gap’ in the cell bed after treatment with SDF-1α (200 ng/mL) compared to basal vehicle-treated conditions. 
Pretreatment with FIL2 at 0.01-1µM concentrations strongly reduced SDF-1α-mediated effects on cell 
motility (Figure 7A). Moreover, FIL2 exposure significantly reduced the increase in the colony numbers 
observed after SDF-1α treatment (Figure 7B).  
Stimulation of CXCR4 by SDF-1 induces phosphorylation of Akt and p42/44 MAPK, promoting 
proliferation and migration of different types of cells [35]. Thus, we conducted time-course studies to 
analyze whether FIL2 compound was able to antagonize the effects of SDF-1α on activation of the above 
mentioned downstream signaling molecules (Figure 7C&7D). As expected, treatment with SDF-1α resulted 
in an increased phosphorylation of Akt and MAPK in MDA-MB-231 breast cancer cells. Interestingly, 
pretreatment with FIL2 abrogated the SDF-1α activation of these signaling pathways.  
  
Figure 7. FIL2 compound antagonizes SDF-1α–mediated motility, growth and signalling activation in MDA-MB-
231 breast cancer cells. (A) Wound-healing assay in cells treated with vehicle (-), SDF-1α (200 ng/mL) with or 
without FIL2 compound (0.01, 0.1, 1µM). Small squares, time 0. (B) Soft agar anchorage-independent growth assay in 
cells treated with vehicle (-), SDF-1α (200 ng/ml) in the presence or not of FIL2 compound (1µM). (C) Immunoblotting 
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of phosphorylated (p) Akt and MAPK and total proteins from cells treated with SDF-1 (200 ng/mL for 5 and 10 
minutes) with or without FIL2 compound (1µM). (D) Histograms represent the mean ± SD of three separate 
experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as 
percentage of control which was assumed to be 100%. *P<0.05, **P<0.005.  
 
 
Efficacy of FIL2 compound in antagonizing CXCR4 signaling in different breast cancer cell models 
and co-culture systems 
To extend our results, as additional model system for breast cancer we investigated the effects of FIL2 
molecule in affecting growth, and motility of ER-positive MCF-7 breast cancer cells. First, we demonstrated 
SDF-1α and CXCR4 expression in these cells (Figure 8A). As previously shown for MDA-MB-231 cells, 
we found a significant decrease in both anchorage-independent proliferation and migration of MCF-7 breast 
cancer cells after FIL2 exposure (Figure 8B). Again, treatment with SDF-1 at 200 ng/mL concentration 
increased colony numbers and motility of cells, and pretreatment with FIL2 compound reduced SDF-1α-
mediated activities (Figure 8C). Finally, we demonstrated that FIL2 was able to reverse the stimulatory 
effects induced by SDF-1α on the phosphorylation levels of Akt and MAPK (Figure 8D&8E), confirming 
that the FIL2 compound may act as a CXCR4 antagonist in different breast cancer cellular backgrounds.  
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Figure 8. FIL2 effects in MCF-7 breast cancer cells. (A) RT-PCR for SDF-1α, CXCR4 and 36B4 (internal standard). 
NC, negative-control. (B) Soft agar anchorage-independent growth (upper panel) and wound-healing (lower panel) 
assays in cells treated with vehicle (-) or FIL2 compound (1, 10µM). Small squares, time 0. (C) Soft agar anchorage-
independent growth (upper panel) and wound-healing (lower panel) assays in cells treated with vehicle (-), SDF-1α 
(200 ng/mL) with or without FIL2 compound (1µM). Small squares, time 0. (D) Immunoblotting of phosphorylated (p) 
Akt and MAPK and total proteins from cells treated with SDF-1α (200 ng/mL for 5 minutes) with or without FIL2 
compound (1µM). Numbers below the blots represent the average fold change in phospho-proteins/total 
proteins/GAPDH ratio relative to vehicle (-)-treated cells. (E) Histograms represent the mean ± SD of three separate 
experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as 
percentage of control which was assumed to be 100%. *P<0.05, **P<0.005. 
 
 
The behavior of tumor cells seems to be regulated not only by cell autonomous signals, but it also relies on 
heterotypic signals coming from surrounding myofibroblast stromal cells, able to create a specific and local 
microenvironment to tightly control breast cancer proliferation and differentiation. Indeed, fibroblasts 
adjacent to primary breast tumors have higher expression of SDF-1α than those of normal breast tissue and 
through this paracrine signaling, CXCR4 may promote local tumor cell proliferation, motility, and invasion 
[36,37]. Therefore, we examined the ability of FIL2 compound to inhibit breast cancer cell proliferation and 
motility promoted by cancer-associated fibroblasts (CAFs). To this aim, CAFs were isolated from biopsies of 
primary breast tumors and coculture experiments were performed to create ‘in vitro’ conditions that can 
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mimic the complex ‘in vivo’ microenvironment [29,38]. Both MDA-MB-231 and MCF-7 breast cancer cells 
were incubated with phenol-red and serum-free medium (-), or CAF-derived conditioned media (C.M.) in the 
presence or not of FIL2 compound and growth and motility were evaluated (Figure 9). As previously 
demonstrated [29], CAF C.M. significantly increased colony numbers and motility of breast cancer cells. 
Interestingly, treatment with FIL2 compound attenuated growth and migration-promoting activities of CAF 
C.M.  
 
Figure 9. FIL2 reduces growth and migration induced by CAF-derived conditioned media in breast cancer cells. 
Soft agar anchorage-independent growth (upper panel) and wound-healing (lower panel) assays in MDA-MB-231 (A) 
and MCF-7 (B) cells treated with phenol-red and serum-free medium (-), conditioned media derived from CAFs (CAF 
C.M.) with/without FIL2 compound (1µM). *P<0.05, **P<0.01, ***P<0.0005. Small squares, time 0. 
 
It has been recently reported that enhanced CXCR4 signaling is sufficient to drive ER-positive breast cancers 
to an endocrine therapy-resistant phenotype, highlighting CXCR4 signaling as a rational therapeutic target 
also for the treatment of ER-positive, estrogen-independent breast carcinoma [39,40]. Therefore, as a final 
step of this study, we evaluated whether FIL2 compound was able to affect the progression of hormone-
independent and therapeutic-resistant breast cancer cell lines, using other two additional breast cancer 
cellular models. In particular, as experimental cell models for acquired resistance, we used: 1) tamoxifen-
resistant (TR) cells obtained from MCF7 cells cultured with 4-OH tamoxifen over a period of 12 months; 2) 
MCF7 LTED cells, which gradually acquired aromatase inhibitor resistance upon culture in estrogen/steroid-
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free conditions [28]. As shown in Figure 10A&10B, we found increased SDF-1α and CXCR4 expression in 
TR cells and LTED cells compared to parental MCF-7 breast cancer cells. In agreement with a previous 
study [30], resistant cells exhibited a higher basal non-stimulated growth and motility (Figure 10C&10D). 
Treatment with SDF-1α or CAF-derived conditioned medium resulted in an enhancement of growth and 
motility of TR and LTED cells and, again, FIL2 compound had a significant inhibitory effect in basal as well 
as SDF-1α and C.M.-stimulated conditions. 
 
 
 
 
Figure 10. FIL2 compound reduces growth and migration in hormone-resistant breast cancer cells. (A) RT-PCR 
for SDF-1α, CXCR4 and 36B4 (internal standard). NC, negative-control. (B) Histograms represent the mean ± SD of 
three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units and 
expressed as percentage of control, which was assumed to be 100%. Soft agar anchorage-independent growth (upper 
panel) and wound-healing (lower panel) assays in tamoxifen-resistant MCF-7 TR (C) and long term-estrogen deprived 
MCF-7 LTED (D) breast cancer cells treated with vehicle (-), SDF-1α (200 ng/mL), conditioned media derived from 
CAFs (CAF C.M.) with or without FIL2 compound (1µM). *P<0.05, **P<0.005, ***P<0.0005. Small squares, time 0. 
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CONCLUSION 
CXCR4 plays a role in several pathophysiological conditions such as cancer, altered immune conditions and 
HIV infection, hence chemical agents able to prevent the interaction between this receptor and its 
endogenous ligand SDF-1 might result useful in the management of a number of pathologies [5-9]. Despite 
the huge number of identified CXCR4 antagonists, most of them show inadequate bioavailability, that 
represents the bigger limit to a clinical application. Thus, only a few compounds have so far entered clinical 
trials [11-15]. Among the small-molecule antagonists, indole based compounds, suitably modified, seem to 
meet pharmacokinetic requirements and optimal features to interact with the target.  
In the present study, we describe the design and the synthesis of three novel molecules namely FIL1-3 
investigated for their capability to interact with CXCR4. In particular, one of the derivatives shows the 
ability to bind to CXCR4 as revealed by molecular docking and whole cell-based [125I]-SDF-1α ligand 
competition binding assays. This compound is able to inhibit SDF-1α-mediated cell motility, proliferation 
and downstream signaling activation in different breast cancer cell lines as well as to prevent tumor 
microenvironment stimulatory effects in co-culture studies. This activity assumes a great importance in 
hormone-resistant breast cancer cell lines, as resistance to endocrine therapy still remains a major clinical 
concern. 
Since breast cancer progression has been correlated to the SDF-1α-CXCR4 signaling axis, specific agents 
able to prevent this interaction, could result of great interest for the management of such a type of cancer.   
Based on these findings, we may consider FIL-2 as a lead for the development of a new class of selective 
antagonist ligands of CXCR4 that may be useful in order to better assess the biological function of this 
receptor. In addition, the CXCR4 antagonism may represent a starting point for the development of novel 
therapeutics for the treatment of breast cancer and other diseases in which the receptor is involved.  
 
FUTURE PERSPECTIVE  
The role played by the interaction of CXCR4 and its natural ligand SDF-1 in several types of tumors, 
including breast cancer, as well as in other diseases is clearly recognized. This suggests that CXCR4 
represents a promising target for the development of innovative therapeutics and the identification of FIL2, 
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as a selective targeting CXCR4 lead compound, may help the discovery of effective CXCR4 antagonists to 
be proposed to clinical practice. Moreover, the possibility to prepare a FIL2 79Br- or 81Br-radiolabeled 
derivative to be used as functional biomarkers in early diagnosis, disease prevention, and drug response may 
represent a further applicative development for the class of compounds herein described. 
 
EXECUTIVE SUMMARY 
 
CXCR4 Inhibition  
Inhibition of CXCR4 represents a promising therapeutic approach in the treatment of breast cancer and other 
diseases involving this receptor. 
 
Lead identification and synthesis 
A new selective CXCR4 antagonist has been identified and could be useful for a rational design of broad-
spectrum therapeutics. 
 
Binding assay  
A whole cell-based [125I]-SDF-1α ligand competition binding assay was accomplished in order to verify that 
FIL2 binds to the CXCR4 receptor as hypothesized by molecular docking prevision. 
 
DEFINED KEY TERMS 
Docking simulation:  
Computational simulation technique used to predict the binding orientation of a candidate ligand into the 
active site of the target protein. 
 
Mapping of the active binding site: 
The assignment of chemical features for the definition of topology in the interaction site of a receptor.   
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Poly-substituted indoles: 
Molecules based on an indole scaffold bearing substituents capable to bind specific groups of the active site 
of a target molecule. 
 
Acquired endocrine resistance: 
Despite the significant advances in the treatment of breast cancer following the introduction of endocrine 
therapy (tamoxifen and aromatase inhibitors), in many estrogen receptor-positive breast tumors drug 
resistance develops during treatment leading to disease progression (acquired resistance). 
 
Tumor microenvironment: 
The behavior of malignant cells seems to be dependent not only on cell autonomous signals, but it also relies 
on heterotypic signalings deriving from surrounding stromal cells, able to generate a microenvironment to 
tightly control breast tumor progression. Among the stromal cells, cancer-associated fibroblasts (CAFs) play 
a crucial role in determining cancer proliferation and differentiation. 
 
Soft agar growth assay: 
The soft agar colony formation assay is a technique used to evaluate cellular anchorage-independent 
proliferation in vitro. This assay is considered to better reflect in vivo three-dimensional tumor growth. 
 
Ligand binding assay: 
Detection method used to evaluate the interactions that occur between two molecules, such as a receptor and 
its ligands.  
 
Coculture experiments: 
Coculture experiments were performed by incubation of breast cancer cells with CAF-derived conditioned 
media. This allows to create in vitro conditions that can mimic the complex in vivo microenvironment. 
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